SI
AMLX icon

Sofinnova Investments’s Amylyx Pharmaceuticals AMLX Stock Holding History

Sofinnova Investments’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-527,099
Closed -$6.37M – 76
2025
Q4 		$6.37M Buy
+527,099
New +$7.16M 0.27% 44
2024
Q3 		– Sell
-299,691
Closed -$569K – 65
2024
Q2 		$569K Sell
299,691
-7,038
-2% -$13.6K 0.03% 75
2024
Q1 		$871K Buy
+306,729
New +$4.01M 0.05% 60
2022
Q3 		– Sell
-187,381
Closed -$3.61M – 59
2022
Q2 		$3.61M Buy
187,381
+87,381
+87% +$1.04M 0.3% 47
2022
Q1 		$1.28M Buy
+100,000
New +$2.26M 0.1% 54

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Sofinnova Investments's AMLX Position: Q1 2026 in Review

Sofinnova Investments sold out of Amylyx Pharmaceuticals (AMLX) in Q1 2026, closing a stake of 527,099 shares — an estimated $6.37M sold.

Sofinnova Investments first reported a position in AMLX in Q1 2022 and held it in 5 quarters. The position peaked at $6.37M in Q4 2025. 171 funds tracked by Wall St. Rank hold AMLX as of Q1 2026.

  • Sofinnova Investments reported no remaining Amylyx Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Sofinnova Investments sold 527,099 Amylyx Pharmaceuticals shares in Q1 2026, an estimated $6.37M.
  • Sofinnova Investments first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 5 quarters.
  • Sofinnova Investments's Amylyx Pharmaceuticals position peaked at $6.37M in Q4 2025.
  • 171 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.